Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
106.18
-1.75 (-1.62%)
After Hours: 106.28 +0.10 (0.09%)
Jul 26, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 105.49 - 108.03
52 week 92.98 - 136.40
Open 105.99
Vol / Avg. 6.51M/4.77M
Mkt cap 82.56B
P/E 51.37
Div/yield     -
EPS 2.07
Shares 774.60M
Beta 1.21
Inst. own 81%
Jul 28, 2016
Q2 2016 Celgene Corp Earnings Release - 9:30AM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Celgene Corp Earnings Call - 9:00AM EDT - Add to calendar
Jun 16, 2016
Celgene Corp Annual Shareholders Meeting (Estimated)
Jun 15, 2016
Celgene Corp Annual Shareholders Meeting
Jun 9, 2016
Celgene Corp at Jefferies Healthcare Conference
Jun 8, 2016
Celgene Corp at Goldman Sachs Global Healthcare Conference
Jun 2, 2016
Celgene Corp at Sanford C Bernstein Strategic Decisions Conference
May 25, 2016
Celgene Corp at UBS Global Healthcare Conference
May 17, 2016
Agios Pharmaceuticals Inc Conference Call To Discuss New Metabolic Immuno-Oncology Collaboration with Celgen - Webcast
May 11, 2016
Celgene Corp at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 31.88% 17.31%
Operating margin 40.77% 23.83%
EBITD margin - 32.01%
Return on average assets 12.14% 7.23%
Return on average equity 58.43% 25.75%
Employees 6,971 -
CDP Score - 97 C

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Officers and directors

Robert J. Hugin Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jacqualyn A. Fouse Ph.D. President, Chief Operating Officer, Director
Age: 55
Bio & Compensation  - Reuters
Mark J. Alles Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Chairman - Celgene Research
Age: 62
Bio & Compensation  - Reuters
Scott A. Smith Global President - Inflammation & Immunology
Age: 54
Bio & Compensation  - Reuters
Rupert Vessey President - Research and Early Development
Bio & Compensation  - Reuters
Gerald F. Masoudi Executive Vice President, General Counsel and Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 57
Bio & Compensation  - Reuters